Company Filing History:
Years Active: 2008-2011
Title: Yoram Cohen: Innovator in Cancer Research
Introduction
Yoram Cohen is a prominent inventor based in Baltimore, MD, known for his significant contributions to cancer research. He has been instrumental in advancing our understanding of genetic mutations associated with various cancers, particularly through his work on the BRAF gene.
Latest Patents
Yoram Cohen holds two patents related to the BRAF gene and its implications in human cancers. His latest research focuses on the BRAF T1796A mutation, which has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. In a study involving 476 primary tumors, including various types of cancers, Cohen and his team utilized polymerase chain reaction (PCR)-restriction enzyme analysis to identify the BRAF T1796A mutation. They discovered that this mutation was present in a significant percentage of papillary thyroid carcinomas and suggested that activating BRAF mutations may play a crucial role in the development of this type of cancer. Furthermore, the presence of the BRAF mutation has been shown to reliably predict a poor prognosis for patients with papillary thyroid carcinomas.
Career Highlights
Cohen's career is marked by his dedication to cancer research and his role at The Johns Hopkins University, where he continues to explore the genetic underpinnings of cancer. His work has not only contributed to scientific knowledge but has also paved the way for potential therapeutic interventions.
Collaborations
Throughout his career, Yoram Cohen has collaborated with esteemed colleagues, including David Sidransky and Mingzhao Michael Xing. These collaborations have further enriched his research and expanded the impact of his findings in the field of oncology.
Conclusion
Yoram Cohen's innovative work on the BRAF gene has significantly advanced our understanding of cancer genetics. His contributions continue to influence research and treatment strategies in oncology, highlighting the importance of genetic mutations in cancer development and prognosis.